Related Experiment Videos
Few new drugs deserve expedited regulatory treatment
1Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Journal of Managed Care & Specialty Pharmacy
|April 28, 2021
Abstract:
DISCLOSURES: This commentary is based on work by the author that was supported by Arnold Ventures and the Harvard-MIT Center for Regulatory Science. The funders had no role in the writing of this commentary, or the decision to submit for publication. The author has nothing else to disclose.